


USE OF PROCALCITONIN TO SUPPORT ANTIMICROBIAL STEWARDSHIP A Selection of Clinical Cases



Devendra Amin, MD, FCCM, FCCP

 Medical Director Critical Care Services, Morton Plant Hospital, Baycare Health System, Florida, USA

John Boreyko, PharmD, BCIDP

 Clinical Infectious Diseases Pharmacist, Co-Director Antimicrobial Stewardship, Duke Regional Hospital, Durham, North Carolina, USA

Ricard Ferrer, MD, PhD

 Head of Intensive Care Department/SODIR Research group-VHIR, Hospital General Universitari Vall d'Hebron, Barcelona, Spain

Evangelos J. Giamarellos-Bourboulis, MD, PhD, FISAC

- Professor of Internal Medicine and Infectious Diseases
- Director: Master (MSc) Program of Infectious Diseases, National and Kapodistrian University of Athens, Greece

📕 Andrea Kwa, PharmD

 Infectious Diseases Specialist Pharmacist, Pharmacy Department, Singapore General Hospital, Associate Professor, Emerging Infectious Diseases Programme, Duke-National University of Singapore Medical School, Singapore

Chien-Chang Lee, MD, Sc.D

 Associate Professor of Emergency Medicine, National Taiwan University Hospital, Taiwan

Zhifeng Liu, MD, PhD

 Associate Senior Physician, Department of Critical Care Medicine, General Hospital of Southern Theatre Command of PLA, China

Zsolt Molnar, MD, PhD, EDAIC

- Institute for Translational Medicine, School of Medicine, University of Pécs, Hungary
- Department of Anesthesiology and Intensive Therapy, Poznan University of Medical Sciences, Poznan, Poland

Manuel Poblano, MD, MHA

• Critical Care, Hospital H+ Querétaro, Mexico

V. Ramasubramanian, MD, FRCP, DTM & H, DGUM

- Professor, Director The Capstone Clinic
- Senior Consultant in Infectious Diseases & Tropical Medicine, Apollo Hospitals, Chennai, India

Guy A Richards*, MBBCh, PhD, FCP (SA), and Zainub Jooma**, MD

* Emeritus Professor Pulmonology/Critical Care, University of the Witwatersrand

** Associate Lecturer, Department of Anaesthesia, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, Gauteng Province, South Africa

This educational booklet was created with the kind participation of the following contributors.

> We are deeply grateful to them for providing clinical cases and valuable discussion of the practical use of procalcitonin to support antimicrobial stewardship.



PREFACE

Overuse of antimicrobials, and largely antibiotics, has been recognized as a main driver for the increase in multi-drug resistant pathogens posing a dramatic threat to global health. Therefore, **reducing antibiotic overuse by improving antimicrobial stewardship** efforts is of high global interest. As clinical signs and symptoms of infection and sepsis may be ambiguous, the identification of **objective diagnostic and prognostic parameters** are needed to improve the decision to start antimicrobial therapy if necessary, and to define the optimal duration. This is particularly true because current treatment duration is mostly based on fixed antibiotic regimens recommended by practice guidelines. Individualizing antibiotic therapy therefore has great potential to improve antimicrobial stewardship and thereby reduce the overall treatment exposure.

In this regard, **procalcitonin (PCT)**, **a serum biomarker** produced in response to bacterial infection, has been found to be most helpful. PCT is upregulated in epithelial cells upon contact with bacterial pathogens within six to twelve hours. Viral infection on the other hand leads to downregulation of its expression, which gives **PCT a diagnostic advantage over other inflammatory markers**. Once the infection is controlled by the host's immune system or by antibiotic therapy, PCT levels halve daily. Thus, PCT helps to discriminate between bacterial and viral infections, thereby helping to define whether antibiotics should be started in patients with unclear clinical pictures, and also provides prognostic information as a marker mirroring the severity of infection and treatment response over time. By tracking the resolution of infection, PCT also allows antibiotic treatment to be discontinued earlier.

Importantly, with the current **COVID-19 pandemic**, respiratory tract infections have again become a main center of attention. While the reduction of antibiotic overuse has been a main goal for PCT-guided antimicrobial stewardship, missing a bacterial sepsis in a patient with suspicion of COVID-19 is also a frequent problem with negative influence on patient outcome. In this case, the **high positive predictive value** of an **increased PCT level in a patient with COVID-19 infection** may help to draw the attention of the treating team to a bacterial infection, thereby improving adequate initial antibiotic management.

It is important to understand the kinetics and also the strengths and limitations of PCT for its safe and effective use in clinical practice. In this context, in addition to reading results of robust research trials, the **discussion of individual patient cases is extremely helpful** to understand the role of PCT in different clinical situations. Within this booklet, we have gathered such **illustrative cases from worldrenowned experts** in the field to help readers better understand how PCT may be used most effectively. Cases are also related to specific clinical studies and thereby help make the transition from the theory of clinical studies to the practical aspects of patient management.

I would like to express my gratitude to all participating experts for sharing their insights with us in order to **further advance the optimal use of PCT for patient care**.



Professor Philipp Schuetz, MD, MPH

Head of Internal Medicine and Emergency Medicine, Kantonsspital Aarau, Tellstrasse H7, CH-5001 Aarau, Professorship and faculty at the University of Basel, Switzerland

 Schuetz P, Beishuizen A, Broyles M, et al. Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use. *Clin Chem Lab Med.* 2019;57(9):1308-1318
 Neeser O, Branche A, Mueller B, Schuetz P. How to: implement procalcitonin testing in my practice. *Clin Microbiol Infect.* 2019;25(10):1226-1230

Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute
respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018;18(1):95-107

CONTENTS

SEPSIS

Early PCT-guided antibiotic discontinuation protects from long-term infection sequelae	
PCT to support clinical decision to discontinue antibiot	ic
therapy	. 9
Using PCT kinetics to guide antibiotic therapy in the critically ill	11
Using PCT to differentiate viral from bacterial pneumor in COVID-19 patients	nia 15
Utility of PCT in the COVID-19 era for diagnosis of	
bacterial sepsis	19
Serial PCT testing reveals bacterial superinfection in ca	ise
of severe COVID-19 pneumonia	21
PCT to support antibiotic stewardship in management patients with COVID-19 pneumonia	

RESPIRATORY TRACT INFECTIONS

PCT helps differentiate b	etween viral and bacterial
infections in LRTI	
PCT combined with PCR	to guide empiric antibiotics in
patients with viral RTIs	
PCT to aid in treatment of	of RTIs and reduce antibiotic
over-prescription	
Using PCT to stop unnec	essary antibiotic use safely39


CONCLUDING REMARKS 41

DISCLAIMER

This document provides experts' experience and actual case studies regarding the practical use of Procalcitonin (PCT) measurement and interpretation of results to support antimicrobial stewardship. The views presented in this educational resource are the authors' personal opinions and do not necessarily represent the viewpoint, strategy or opinions of bioMérieux.

Furthermore, the content of this document does not relieve the clinician of the obligation to verify the interpretation of the laboratory result based on their clinical knowledge, to assess the clinical status of each individual patient, and to decide on appropriate treatment.

Neither bioMérieux, nor the contributors, assume any liability for any injury and/or damage to persons arising from the information published. Liability claims regarding damage caused by the use of any information provided, including any information which is incomplete or incorrect, will therefore be rejected.



PCT CLINICAL CASES

SEPSIS



Evangelos J. Giamarellos-Bourboulis, MD, PhD, FISAC

Professor of Internal Medicine and Infectious Diseases, Director: Master (MSc) Program of Infectious Diseases, 4th Department of Internal Medicine, National and Kapodistrian University of Athens, **GREECE**

EARLY PCT-GUIDED ANTIBIOTIC DISCONTINUATION PROTECTS FROM LONG-TERM INFECTION SEQUELAE

C	89-year-old female
S	Past history of chronic heart failure
On ED admission	 Patient experienced pain on palpation of the right costovertebral angle qSOFA score of 2 (mental confusion and 30 breaths/minute), BP: 128/54 mmHg, T: 37.8°C, p02/Fi02: 292mmHg, lactate: 2.6 mmol/L In the ward, Glasgow Coma Scale: 12, SOFA score: 4, CRP: 41.8 mg/dL, PCT: 42.3 ng/mL, total WBC count: 10.57x10⁹/L, p02/Fi02: 292 mmHg Treatment started with intravenous ciprofloxacin
After 24 hours	 Patient was afebrile Results of urine and blood culture revealed <i>Escherichia coli</i> with resistance to piperacillin-tazobactam
After 5 days	 Patient remained afebrile and hemodynamically stable No side effects from the use of antibiotics were observed PCT had decreased to 7.5 ng/mL (Figure 1) Decision to stop antibiotics was taken based on the PCT discontinuation rule: decrease of PCT more than 80% from baseline
Patient outcome	On day 6, patient remained afebrile without symptoms and was discharged. After one month: • follow-up urine culture was sterile, • surveillance stool culture to monitor for colonization by resistant <i>E. coli</i> was negative.

After six months, patient showed no long-term

sequelae from the infection.

- Decrease of long-term infection sequelae for 6 months, namely infections by multidrug-resistant microorganisms (MDROs) and *Clostridioides difficile*, achieved through reduction of the odds for colonization by MDRO and *C. difficile* under the pressure of broadspectrum antibiotics.
- Decrease of 28-day mortality associated with decrease of antibioticassociated adverse events (diarrhea and acute renal injury).
- Decrease in the cost of hospital stay.




Figure 1. Evolution of PCT levels from admission to day 5

Supportive literature

 Kyriazopoulou E, Liaskou-Antoniou L, Adamis G, et al. Procalcitonin to reduce long-term infectionassociated adverse events in sepsis: a randomized trial. Am J Respir Crit Care Med. 2021;203(2):202-210



Zhifeng Liu, MD, PhD

Associate Senior Physician, Department of Critical Care Medicine, General Hospital of Southern Theatre Command of PLA, **CHINA**

PCT TO SUPPORT CLINICAL DECISION TO DISCONTINUE ANTIBIOTIC THERAPY



64-year-old female

- Transferred to ICU for acute myocardial infarction, urogenic sepsis, septic shock
- Then transferred to Cardiovascular Medicine with diagnosis of urinary tract infection, multiple kidney stones and acute myocardial infarction



- A

On day 3

On day 4

On day 5

10

On day 13

On day 19

10

- Temperature: 36.8°C, unconsciousness, speech disorder
- PCT: >200 ng/mL, CRP: 332.27 mg/dL, WBC: 37.38x10⁹/L
 - Lymphocytes: 3.3%

Antibiotics started: imipenem/cilastatin sodium

- Temperature: 37.3°C, listless
 - PCT: 138.1 ng/mL, CRP: 124.28 mg/dL, WBC: 14.19x10⁹/L
 - Lymphocytes: 6.2%
- Temperature: 37.8°C, listless
- PCT: 72.82 ng/mL, CRP: N/A, WBC: 10.07x10⁹/L
- Lymphocytes: 11.0%
- Temperature: 37.2°C, listless
- PCT: 34.73 ng/mL, CRP: N/A, WBC: 10.70x10⁹/L
- Lymphocytes: 14.0%
- Blood culture: *E. coli*, AST: piperacillin-tazobactam S (MIC: 4)
- Transfer from ICU to Cardiology Department
- Antibiotics de-escalated: piperacillin-tazobactam
- Temperature: 36.6°C, conscious
- PCT: 0.97 ng/mL, CRP: 8.24 mg/dL, WBC: 9.13x10⁹/L
 Lymphocytes: 15.1%
- Temperature: 36.8°C, conscious and stable vital signs
- PCT: 1.45 ng/mL, CRP: N/A, WBC: N/A
- Lymphocytes: N/A
- PCT dropped by >80% compared with peak level
- No rebound of WBC in urine, no fever
- Antibiotics safely discontinued

Patient outcome

Patient was discharged and not rehospitalized for infection within 3 months after discharge.

- PCT level was initially higher than 200 ng/mL, indicating severe infection, and allowing clinician to start immediate monitoring.
- Daily PCT dynamic monitoring in ICU decreased by about 50% every day, indicating empirical antibiotic treatment was effective.
- Blood culture results of Gram-negative bacilli were in line with the characteristics of high PCT value. Antibiotics were adjusted according to AST results.
- On Day 19, the PCT level decreased by >80% compared with the peak value, which, combined with the patient's infection index (no rebound of urine white blood cells, no fever) enabled the patient to be discharged safely.




Figure 1. Blood levels of PCT and CRP, and temperature

Supportive literature


 Lee CC, et al. Procalcitonin (PCT)-guided antibiotic stewardship in Asia-Pacific countries: Adaptation based on an expert consensus meeting. *Clin Chem Lab Med*. 2020;58(12):1983-91



Zsolt Molnar, MD, PhD, EDAIC

Institute for Translational Medicine, School of Medicine, University of Pécs, **HUNGARY** Department of Anesthesiology and Intensive Therapy, Poznan University of Medical Sciences, Poznan, **POLAND**

USING PCT KINETICS TO GUIDE ANTIBIOTIC THERAPY IN THE CRITICALLY ILL



USING PCT KINETICS TO GUIDE ANTIBIOTIC THERAPY IN THE CRITICALLY ILL




- Putting low PCT values in the context of the clinical picture helps to withhold antibiotics in case of low probability for a bacterial infection in patients who are hemodynamically stable.¹²
- Sudden increase of PCT should be a warning signal (red flag) for new onset infection.³
- If PCT increase is accompanied with new onset or increasing vasopressor need, starting empirical antibiotics early (within 1 hour) should be considered.³⁴
- In cases of new onset infections in the ICU, absolute values and/ or changes of conventional indicators of infection such as temperature, WBC, and CRP can be false negative.³
- Assessment of PCT kinetics after the start of empirical antibiotics (i.e. at 0-12-24 hours) may help to identify antibiotic appropriateness/inappropriateness before microbiology results are available.⁵
- Evaluating daily PCT changes could help to reduce antibiotic exposure, which may have a positive effect on outcomes and costs.⁶

Table 1. Change of condition within first 48 hours

	T ₀	T ₂₄	T ₄₈	
Hemodynamics				
Heart rate (/min)	110	105	95	
MAP (mmHg)	66	70	68	
ScvO ₂ (%)	67	71	68	
Noradrenaline (µg/kg/min)	-	-	-	
Respiratory function				
FiO ₂	0.8	0.7	0.6	
PEEP (cmH2O)	10	10	10	
PaO₂ (mmHg)	86	73	78	
Inflammation				
Temp (°C)	38.6	37.9	37.8	
WBC (10 ⁹ /L)	8.6	8.8	7.8	
CRP (mg/dL)	67	86	153	
PCT (ng/mL)	0.12	0.18	0.16	

ScvO2: central venous oxygen saturation; FiO2: fraction of inspired oxygen; PEEP: positive end expiratory pressure; PaO2: partial pressure of arterial oxygen; Temp: temperature; WBC: white blood cell; CRP: C-reactive protein; PCT: procalcitonin



Supportive literature

- Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, singleblinded intervention trial. *Lancet* 2004;363:600-607
- Maisel A, Neath SX, Landsberg J, et al. Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial. Eur J Heart Fail. 2012;14:278-286
- Trásy D, Tánczos K, Németh M, et al. Delta procalcitonin is a better indicator of infection than absolute procalcitonin values in critically ill patients: a prospective observational study. *J Immunol Res.* 2016: Paper 530752. 9 p.
- 4. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016. *Intensive Care Med*. 2017;43:304-377
- Trásy D, Tanczos K, Nemeth M, et al. Early procalcitonin kinetics and appropriateness of empirical antimicrobial therapy in critically ill patients: A prospective observational study. J Crit Care 2016;34:50-55
- Jong E, Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016;16:819-827



Devendra Amin, MD, FCCM, FCCP

Medical Director Critical Care Services, Morton Plant Hospital, Baycare Health System, Florida, **USA**

USING PCT TO DIFFERENTIATE VIRAL FROM BACTERIAL INFECTION IN COVID-19 PATIENTS

S	 24-year-old male, healthy Hospitalized with increasing shortness of breath, dry cough, chest discomfort and diarrhea for 5-6 days Presenting with low grade fever increasing to 38.8°C in ER Initial oxygen saturation: 85% on room air Chest X-ray showed bilateral inflammatory infiltrates and ground glass changes (Figure 1) Arterial blood gas showed severe hypoxemia pH: 7.42, PaCO₂: 40.5, PaO₂: 46.7 on 5 liters of oxygen
On ICU admission	 Initial inflammatory biomarkers were elevated: CRP: 10 mg/dL, Ferritin: 1554 ng/mL, II-6: 69 pg/mL PCT was not elevated on admission (0.11 ng/mL), suggesting absence of bacterial infection Urinary antigens for Streptococcus pneumoniae and Legionella pneumoniae were negative Viral PCR was negative for influenza A, B and RSV COVID-19 nasal PCR was positive Patient was hospitalized due to the severity of illness Antibiotics started for CAP: cefuroxime, azithromycin and dexamethasone followed by remdesivir for COVID-19 pneumonia
ofter 24 hours	 Patient's oxygen requirements went up Transferred to ICU for BiPAP, then very quickly needed intubation for progressive hypoxic respiratory failure PCT remained low: <0.05 ng/mL (Figure 2) Antibiotics were discontinued at 48 hours
Iver next days	 Patient's condition continued to worsen, despite aggressive recruitment maneuvers, including bi-level ventilation and prone ventilation Pa02/Fi02 remained <100 Decision made to insert canulae for veno-venous ECMO (Figure 3)

Patient outcome


Despite EMCO support, patient continued to have dense bilateral infiltrates and stiff lungs. The outcome was complicated by a MRSA pneumonia with bacteremia and a pneumothorax on right side (Figure 4). While still on ECMO, the patient sustained a cardiac arrest and died 97 days after admission.

- Historically, patients with infiltrates were treated with antibiotics as the assumption was that it was almost always a bacterial infection.
- The COVID-19 pandemic has proven that viral infections can produce equally exuberant infiltrates as bacterial infections.
- To prevent overuse and unnecessary duration of antibiotics, using PCT to differentiate bacterial from viral infections is very helpful in appropriate antibiotic stewardship, without compromising patient safety.
- White blood cell count is non-specific in differentiating bacterial from viral infection. CRP is also elevated in both conditions. However, PCT levels do not generally go up with a viral infection even in very severe cases, as illustrated here.
- Therefore, presence of a normal PCT allows for safe discontinuation of antibiotics within 24 to 48 hours if no other evidence for a bacterial infection.
- We feel that the combination of rapid viral PCR testing and a negative PCT allows for greater confidence in safe antibiotic stewardship.

Supportive literature

- Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in communityacquired pneumonia - a randomized trial. Am J Respir Crit Care Med. 2006;174(1):84–93
- Sager R, Kutz A, Mueller B, et al. Procalcitonin-guided diagnosis and antibiotic stewardship revisited.
 BMC Med. 2017;15(1):15
- Heesom L, Rehnberg L, Nasim-Mohi M,, et al. Procalcitonin as an antibiotic stewardship tool in COVID-19
 patients in the intensive care. J Glob Antimicrob Resist. 2020;22:782-784
- Lee CC, Chang JC, Mao XW, et al. Combining procalcitonin and rapid multiplex respiratory virus testing for antibiotic stewardship in older adult patients with severe acute respiratory infection. J Am Med Dir Assoc. 2020;21(1):62-67

USING PCT TO DIFFERENTIATE VIRAL FROM BACTERIAL INFECTION IN COVID-19 PATIENTS







Figure 3. Chest X-ray during ECMO







Manuel Poblano, MD, MHA Critical Care, Hospital H+ Querétaro, MEXICO

UTILITY OF PCT IN THE COVID-19 ERA FOR DIAGNOSIS OF BACTERIAL SEPSIS



44-year-old female

- Presented to the ED with high fever, shortness of breath, diarrhea, distal cyanosis
- BP: 65 mm/Hg, HR: 150/min, SpO₂: 78%, with ARDS
- Past medical history of systemic hypertension and obstructive sleep apnea syndrome (OSAS) treatment with nocturnal nasal CPAP
- Transfer to ICU with diagnosis of ARDS secondary to COVID-19
 and suspicion of pulmonary thromboembolism



On day 2

- Patient required invasive mechanical ventilation
- Chest CT scan showed bilateral hypoperfusion areas and diffuse bilateral pulmonary infiltrates; echocardiogram with TAPSE of 8 and enlarged right ventricle
- BP: 60/25 mm/Hg, metabolic acidosis, lactate: 5.6 mmol/L, creatinine: 4.1 mg/dL, D-dimer: 34,000 ng/mL
- PCR: 24.5 and PCT: 95.8 ng/mL, WBC: 12.23x10⁹/L, SOFA: 7
- Patient suffered two cardiac arrests in the ICU
- Due to strong suspicion of pulmonary thromboembolism, thrombolysis with rtPA was given
- Broad spectrum antibiotic coverage was given in the first 2 hours (meropenem plus vancomycin) due to elevated PCT
- Patient was admitted to respiratory ICU
- PCR for SARS-CoV-2 came back negative
- Blood cultures were obtained in the ED, became positive after 12 hours and the Gram stain showed Gram-negative bacilli
- Abdominal ultrasound and abdominal CT scan were performed and a diagnosis of acute cholecystitis and gallbladder empyema was made
- Patient had a cholecystectomy 48 hours after admission
- · After surgery, the patient stabilized
- PCT levels decreased in the first 48 hours
- Final blood culture results were E. coli ESBL
- Vancomycin was stopped and after 72 hours of meropenem, the patient was de-escalated to ertapenem (i.e. 10 days of antibiotic treatment)

Patient outcome

Patient was discharged 12 days after admission, without any renal or neurological sequelae.

- PCT is a useful marker to determine the severity of illness. The treatment of intra-abdominal infections based on the PCT algorithm shortens the duration of antibiotic treatment and does not pose a risk for recurrence of the infection.
- In this specific clinical case, PCT helped the doctors to look for another source of infection than the lungs.
- Due to the severity of the patient's condition and in the context of the COVID-19 pandemic, the initial diagnosis was COVID-19 and PCT was a key factor in making the diagnosis and prognosis for the patient.
- In the COVID-19 era, not all cases of septic shock are due to COVID-19!



Figure 1. PCT kinetics over hospitalization period

Supportive literature

 Reith H, Mittelkötter U, Wagner R, et al. Procalcitonin (PCT) in patients with abdominal sepsis. Intensive Care Med. 2000;26:S165–S169

 Mahmutaj D, et al. The predictive role of procalcitonin on the treatment of intraabdominal infections. Open Access Maced J Med Sci. 2017;5(7):909-914



Ricard Ferrer, MD, PhD

Head of Intensive Care Department/ SODIR Research group-VHIR, Hospital General Universitari Vall d'Hebron, Barcelona, SPAIN

SERIAL PCT TESTING REVEALS BACTERIAL SUPERINFECTION IN SEVERE COVID-19 PNEUMONIA

 49-year-old male Presented to ED with asthenia and dyspnea Past medical history included arterial hypertension treated with enalapril Myalgia and dry cough reported for the last seven days Asthenia and dyspnea developing in the 48 hours prior to medical consultation 	On day 2	 Patient was hospitalized due to COVID-19 pneumonia and remained stable with sustained oxygen saturation and no increase in oxygen demands Sputum culture was negative Serial determinations of PCT performed during first two days of hospitalization gave values <1 ng/mL Empiric antibiotic therapy stopped On day four, patient developed a decrease in oxygen
 HR: 105 bpm, tachypnea (RR: 24/min) Bilateral dry crackles on respiratory auscultation SpO₂: 87% without supplementary oxygen Axillary temperature: 37°C 	On day 4	saturation, with increased difficulty breathing and was transferred to ICU • Patient admitted to ICU • High-flow oxygen therapy started with FiO ₂ 0.8 - 50L/min
 Community-acquired pneumonia was suspected Oxygen therapy was delivered by a Venturi mask, with a fraction of inspired oxygen (FiO₂) of 0.35 Blood gas analysis showed PaO₂: 71 mmHg (FiO₂ 0.35), 		 Chest X-rays showed worsening infiltrates Progression of the viral pneumonia was suspected PCT remained low (0.8 ng/mL) Antibiotics were not initiated and dexamethasone
 PaCO2: 41 mmHg, Hb: 12 g/dL, lactate: 1.5 mmol/L Blood test showed predominantly polymorphonuclear leukocytosis (total WBC count 18x10⁹/L, neutrophil count 16x10⁹/L) with lymphopenia (900x10⁹/L) Further blood tests included D-dimer (900 ng/mL), IL-6 (650 pg/mL) and CRP (1.5 mg/dL) 	On day 5 سوری	 was added to the treatment Patient condition deteriorated Mechanical ventilation required due to acute respiratory failure and increased difficulty breathing Bronchoscopy performed, and lower respiratory tract
 Chest X-ray showed peripheral alveolar infiltrates; echocardiography and electrocardiogram were normal Rapid bacterial and viral diagnostic tests: <i>S. pneumoniae,</i> <i>L. pneumophila,</i> Gram stain, Influenza were negative Nasopharyngeal swab for SARS-CoV-2 was positive 		 No clinical signs of bacterial superinfection PCT remained stable Decision to withhold antibiotics, based on low PCT.
 Suspicion of possible bacterial coinfection Ceftriaxone and azithromycin started 	On day 9 العناية	 Patient developed progressive hypoxemia and persistent fever Chest X-rays showed condensation in right lower quadrant Peripheral blood tests showed polymorphonuclear leukocytosis (total WBC: 20x10⁹/L) IL-6 (30000 pg/mL), CRP (15 mg/dL) and PCT (160 ng/mL) used as confirmatory biomarkers Ventilator-associated pneumonia suspected; blood/respiratory cultures obtained Meropenem started as empiric antibiotic therapy

On ED admission (day 1)

SERIAL PCT TESTING REVEALS BACTERIAL SUPERINFECTION IN SEVERE COVID-19 PNEUMONIA



- Patient showed progressive respiratory improvement
- Endotracheal aspirate positive for a strain of Pseudomonas aeruginosa susceptible to all antibiotics tested
- Antibiotic therapy de-escalated to ceftazidime
- Within 3 days of antibiotic therapy initiation, **PCT levels decreased to 5 ng/mL**
- After 5 days of antibiotic therapy,
 PCT levels had reached baseline levels
- Antibiotics discontinued


Patient outcome

Patient was weaned from mechanical ventilation after 20 days and discharged from ICU on day 24.



- The prevalence of laboratory-confirmed bacterial superinfection in severe COVID-19 patients could be up to 25%, ¹ especially in patients admitted to the ICU.²
- Several studies have reported that elevated PCT is positively associated with the severity of COVID-19.³⁴ Serial PCT measurements may be of prognostic value⁵ in predicting evolution towards a more severe form of the disease and complications such as ventilatorassociated pneumonia.

Figure 1. Kinetics of PCT and other blood biomarkers from day 1 to day 24



Supportive literature

- Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020;81(2):266–275
- Garcia-Vidal C, Sanjuan G, Moreno-García E, Martínez JA, Soriano A. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. *Clin Microbiol Infect*. 2020;S1198-743X(20)30450-X
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506
- 4. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720
- 5. Hu R, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. Int J Antimicrob Agents. 2020;56(2):106051



Guy Richards*, MBBCh, PhD, FCP (SA)

and Zainub Jooma**, MD

- * Emeritus Professor Pulmonology/Critical Care, University of the Witwatersrand
- ** Associate Lecturer, Department of Anaesthesia, Charlotte Maxeke, Johannesburg Academic Hospital Johannesburg, Gauteng Province, SOUTH AFRICA

PCT TO SUPPORT ANTIBIOTIC STEWARDSHIP IN MAN AGEMENT OF PATIENTS WITH COVID-19 PNEUMONIA



51-year-old female healthcare worker

- Presented to ED with features of COVID-19 pneumonia confirmed by PCR testing
- Comorbidities: hypertension and obesity (BMI 35)
 Description:
- Respiratory support administered via non-invasive ventilation
- Received steroids, tocilizumab, empiric antibiotics and therapeutic anticoagulation
- On ICU admission

On Day 6

- Admitted to ICU with worsening dyspnea and hypoxemia
- Patient was intubated and ventilated
 Initial PaO₂/FiO₂ ratio of 81, CRP: 65 mg/dL, PCT: 0.08 ng/mL, blood cultures negative
- → Antibiotics stopped based on low PCT result
- Patient was extubated post-admission as gases had improved considerably
- However, extubation failed and patient was re-intubated on Day 7 with a PaO₂/FiO₂ ratio of 85 on an airway pressure release (APRV) mode
- CRP and PCT remained low

On Day 17

- PCT rose to 10.93 ng/mL and CRP to 84 mg/dL
- Source of sepsis uncertain
- Appropriate investigations; invasive lines changed
- Empiric antibiotics started: ertapenem and amikacin according to the epidemiology of the unit

Day 18

Day 19

1

• PCT: 45.65 ng/mL

- Blood culture flagged positive for *Klebsiella pneumonia* sensitive to ceftriaxone and ciprofloxacin
- Antibiotics de-escalated
- Blood cultures repeated
- CRP rose to 225 mg/dL and PCT decreased to 33.6 ng/mL
- Blood culture now grew an Acinetobacter baumanii species sensitive to colistin
- Antibiotics were left unchanged, however, given the decreasing PCT result

 CRP showed no response (222 mg/dL) but PCT halved to 16.11 ng/mL and both biomarkers then continued on

On Day 20

- a downward trajectory
- Patient completed 6 days of ceftriaxone
- Antibiotics stopped when PCT was 1.32 ng/mL and CRP 78 mg/dL

Patient outcome


Patient remained in ICU for 31 days. No further episodes of sepsis occurred. Patient was discharged to ward for rehabilitation post-COVID-19 pneumonia.

PCT TO SUPPORT ANTIBIOTIC STEWARDSHIP IN MAN AGEMENT OF PATIENTS WITH COVID-19 PNEUMONIA



- If performed daily, PCT is of value in deciding on initiation of antibiotics and may also allow earlier discontinuation when the patient has recovered.
- The article by Schuetz et al. Lancet Infect Dis. 2018;18(1):95-107 supports this practice. However, it is important that the trend is followed rather than an isolated measurement. In addition, PCT only works as a stewardship tool if the result is believed and acted upon.
- Furthermore, if another more resistant organism is cultured while PCT levels are dropping, escalation of antibiotics may not be necessary. However, PCT should still be measured daily to allow these decisions to be made and patients should be carefully monitored after stopping antibiotic treatment in case of late treatment failure.
- PCT can rise with other causes of inflammation and with trauma. It is important to know the values associated with infection for each specific laboratory as in some laboratories sepsis may only be likely if values >5 or >10 ng/mL occur.
- Access to viral PCR, and in this case, SARS-CoV-2 PCR can significantly reduce antibiotic use.


Figure 1. Kinetics of the inflammatory markers: blood levels of PCT and CRP in a case of COVID-19 pneumonia with secondary bacterial sepsis.



- PCT and CRP kinetics are evident in Figure 1
- Whereas CRP rose and fell randomly, PCT rose only in association with an episode of sepsis

Supportive literature

- Torres A, Artigas A, Ferrer R. Biomarkers in the ICU: less is more? No. Intensive Care Med. 2020. https://doi.org/10.1007/s00134-020-06271-4
- Schuetz P, Wirz Y, Sager R, Christ-Crain M, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018;18(1):95-107
- Hellyer TP, McAuley DF, Walsh TS, Anderson N, et al. Biomarker-guided antibiotic stewardship in suspected ventilator-associated pneumonia (VAPrapid2): a randomised controlled trial and process evaluation. Lancet Respir Med. 2020;8(2):182-191
- Moradi T, Bennett N, Shemanski S, Kennedy K, Schlachter A, Boyd S. Use of procalcitonin and a respiratory polymerase chain reaction panel to reduce antibiotic use via an electronic medical record alert. Clin Infect Dis. 2020;71(7):1684–9



PCT CLINICAL CASES

RESPIRATORY TRACT INFECTIONS



V. Ramasubramanian. MD, FRCP, DTM & H, DGUM

Professor, Director - The Capstone Clinic, Senior Consultant in Infectious Diseases & Tropical Medicine, Apollo Hospitals, Chennai, INDIA

BACTERIAL INFECTIONS IN LRTI* PCT HELPS DIFFERENTIATE BETWEEN VIRAL AND



58-year-old male, diabetic

- Presented to the ER
- · Fever, vomiting, diarrhea for 7 days
- Breathlessness for 1 day
- Started on piperacillin-tazobactam elsewhere
- Nasopharyngeal swab for SARS-CoV-2 positive
- Heart rate: 110 bpm, blood pressure: 130/80 mmHg, O₂ saturation 91% in room air
- CT scan of chest showed peripheral ground glass opacities consistent with COVID-19
- Started on 4 liters oxygen
- Antibiotics started: remdesivir, enoxaparin, dexamethasone
- TLC: 5720 mL, PCT: 0.16 ng/mL
- Antibiotics stopped
- Repeat PCT after 2 days: 0.01 ng/mL
- On day 5
- Patient developed worsening hypoxia requiring high flow nasal oxygen
- Temperature: 36.8°C, blood pressure: 110/70 mmHg
- TLC: 13200 mL, N: 80%, PCT: 2.6 ng/mL
- Started on meropenem

From day 6 to discharge

1-0-0-

Patient

outcome

- Patient clinically improved in 48 hours • Repeat PCT after 72 hours: 0.56 ng/mL
- Blood cultures grew Klebsiella (ESBL-producer) Repeat PCT after 6 days: 0.12 ng/mL
- Antibiotics stopped

Patient was discharged after 12 days of hospitalization.

CONCLUSIONS

- PCT helps to differentiate between viral and bacterial infections, especially in the context of lower respiratory tract infections.
- Serial PCT levels are useful to assess response in patients with severe infections.
- Monitoring PCT levels in a patient who is showing clinical response can help to stop antibiotics earlier and thereby reduce antibiotic exposure.

Supportive literature

- Self WH, Balk RA, Grijalva CG, et al. Procalcitonin as a Marker of Etiology in Adults Hospitalized with Community-Acquired Pneumonia. Clin Infect Dis. 2017;65:183
- · Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018;18:95

*LRTI: Lower Respiratory Tract Infection



Chien-Chang Lee, MD, Sc.D

Associate Professor of Emergency Medicine, National Taiwan University Hospital, **TAIWAN**

PCT COMBINED WITH PCR TO GUIDE EMPIRIC ANTIBIOTICS IN PATIENTS WITH VIRAL RTIS*



86-year-old female

- Presented to ED with cough, dyspnea and fever of 2 days' duration
- Past medical history of diabetes mellitus, gout, sick sinus syndrome, and congestive heart failure
- On admission, BP: 126/64 mmHg, HR 62 bpm, T: 38.2°C, RR: 22 breaths/minute, SpO₂: 94% on room oxygen
- Blood test results showed hemoglobin: 11.4 g/dL, WBC: 13,850 x 10⁹/L, lymphocytes: 1662/µL, blood urea: 17.2 mg/dL, creatinine: 1.0 mg/dL and NT-proBNP: 5295 pg/mL
- Chest X-ray was essentially clear, except for mild bilateral hilar infiltrates
- On ED admission

- Suspicion of acute heart failure with superimposed lower respiratory tract infection.
- Initiation of ampicillin/sulbactam by injection, diuretic, oxygen therapy, and antipyretics
- The rapid molecular test showed a positive result for respiratory syncytial virus (RSV) and a low PCT level of 0.12 ng/mL confirmed diagnosis of superimposed RSV infection
- Due to low PCT result, initial intravenous antibiotic was discontinued
- Patient was kept on diuretics and oxygen therapy

Dyspnea improved after diuretics and oxygen therapy

• Fever subsided 24 hours after admission


After 24 hours

Patient outcome

Patient was discharged after 3 days hospitalization.

- Respiratory virus infection is a common cause of acute dyspnea in elderly patients, but superimposed bacterial infection occurs in 10% of patients.
- A low PCT level (<0.25 ng/mL) in a patient with a positive molecular test for respiratory virus may help guide clinicians in withholding use of empiric antibiotics in low-risk patients.

Figure 1. Chest X-ray on admission



Supportive literature

- Lee CC, Chang JC, Mao XW, et al. Combining procalcitonin and rapid multiplex respiratory virus testing for antibiotic stewardship in older adult patients with severe acute respiratory infection. J Am Med Dir Assoc. 2020;21(1):62-67
- Maisel A, Neath SX, Landsberg J, et al. Use of procalcitonin for the diagnosis of pneumonia in patients
 presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart
 Failure) trial. *Eur J Heart Fail*. 2012;14(3):278-86

*RTIs: respiratory tract infections



John Boreyko, PharmD, BCIDP

Clinical Infectious Diseases Pharmacist, Co-Director Antimicrobial Stewardship, Duke Regional Hospital, Durham, North Carolina, **USA**

PCT TO AID IN TREATMENT OF RTIS* AND REDUCE ANTIBIOTIC OVER-PRESCRIPTION

•	85-year-old female		
\mathcal{O}	 History of hypertension, COPD, tobacco abuse, osteoarthrit and breast cancer 	tis	50
S	 Chief complaint: increased shortness of breath with cough Found to be hypoxic to high 80s on room air BP: 114/76 mmHg, Pulse: 75 bpm, RR: 33 breaths/minute Suspected condition: respiratory insufficiency with 		PCT can help cause of res suspected of quickly narro
	presumptive diagnosis of Community Acquired Pneumonia (CAP)		suspicion for At our hospit therapy in p clinical susp
On admission	 Patient admitted to medicine floor Chest X-ray revealed patchy infiltrates in mid lobes 		then we will o appropriate (
	suspicious for either pulmonary edema or pneumonia		
	 Empiric therapy initiated: ceftriaxone 1 gram IV q24h + azithromycin 500 mg IV q24h 		Supportive literature
After 12 hours	 WBC: 8.8x10⁹/L, BNP: 144 pg/mL, PCT: <0.1 ng/mL No further chest imaging performed 		20,000 PCT measurement Schuetz P, Briel M, Mu antibiotic therapy in res
	 Patient saturations improved to 97% on 1L O2 Diagnostic-based therapy decision to discontinue ceftriaxone: based on negative procalcitonin, improvement in O2 saturations and no fever 		RTIs: respiratory tract ir
	 Azithromycin was continued for acute exacerbation of COPD 		
Patient outcome	Patient quickly recovered and at discharge had O2 saturations of 97% on room air. No leukocytosis, fever or vital sign abnormalities.		

CONCLUSIONS

- p differentiate between a bacterial and non-bacterial piratory insufficiency. For this patient with initially community-acquired pneumonia, antibiotics were owed based on low PCT levels and therefore low clinical pneumonia with rapid resolution of patient symptoms.
- al we draw initial PCT to assess need for antimicrobial atients presenting with respiratory insufficiency. If icion supports use of antibiotics, but is borderline, obtain a 2nd level and if still negative will de-escalate as (see PCT protocol on pages 37/38).

tinue antibiotics was based on Duke Regional Hospital's experience with over nts and aligned with:

eller Bl. Clinical outcomes associated with procalcitonin algorithms to guide spiratory tract infections. JAMA 2013;309(7):717-718

fections


PCT TO AID IN TREATMENT OF RTIS* AND REDUCE ANTIBIOTIC OVER-PRESCRIPTION

Procalcitonin protocol in use at Duke Regional Hospital

Protocol and algorithms adapted from Schuetz P, Briel M, Mueller BI. Clinical outcomes associated with procalcitonin algorithms to guide antibiotic therapy in respiratory tract infections. JAMA 2013;309(7):717-718

Serum concentrations of PCT are normally <0.05 ng/mL but in circumstances of systemic inflamation, particularly bacterial infection, PCT is produced in large quantities by many body tissues. It is detectable within 2-4 hours and peaks within 6-24 hours.

Emergency Room: exacerbations of bronchitis, COPD or CHF **Recommended use:** based upon evidence, it is recommended that patients who present with symptoms that mimic LRTIs have a PCT value measured with interpretation based on **Algorithm 1**.





Additional algorithms (2 and 3) in use at the Duke Regional Hospital for patients with suspected sepsis/septic shock.

Sepsis Initial Antibiotic Use Algorithm.

Recommended use: based upon evidence, it is recommended that patients admitted to the ICU with presumed sepsis/septic shock have PCT drawn on admission and that PCT be repeated on the next 2 days. Decisions regarding antibiotic therapy can then be made based upon PCT dynamics, culture data, and patient specific clinical data.

*RTIs: respiratory tract infections







Andrea Kwa, PharmD

Infectious Diseases Specialist Pharmacist. Pharmacy Department, Singapore General Hospital, Associate Professor, Emerging Infectious Diseases Programme, Duke-National University of Singapore Medical School, SINGAPORE

USING PCT TO STOP UNNECESSARY ANTIBIOTIC USE SAFELY

-	89-year-
Ç	 Referred by Outpatient Clinic Ser Medical History: IHD, HTN, HLD, T2DM, anemia Hb 10-11, nocturia BPH Symptoms & Complaints: intermittent cough x 1-2/52, r SOB, no fever, no urinary sym Suspected Conditions: Unwitnessed fall precipitated Hypoglycemia? CBG in ED: 4. OHGAs (gliclazide reduced gr - CT brain ordered UTI/Pneumonia? - COVID-19 testing ordered - CXR, CRP, FBC ordered
On ED dmission	 Temp: 35.7°C, BP: 160/76 mm Sp02: 99% on RA Intermittent cough x 1-2/52, r no SOB, no fever No urinary symptoms CT brain done: no established intracranial haemorrhage or n fracture COVID-19 testing negative, CX atelectasis noted in left lower CBG: 8.7-10.2 mmol/L, FBC \$ 9.5x10⁹/L, PIt: 314x10⁹/L, CRF

After 48 hours



old male

vices to ED for unwitnessed fall

with B12 deficiency - baseline

no sore throat/rhinorrhea. no

ptoms

- by: postural hypotension? .1-5.9 mmol. HbA1c: 6.1%. on radually from 160mg BD)
- 1Hg, HR: 92 breaths/minute,
- no sore throat/rhinorrhea.
- territorial infarct, acute nass effect, no skull vault
- R done: minor areas of zones
- Hb: 11.2 g/dL, WBC: P: 5 mg/dL
- Pain Score: 0, Temp: 36.9°C
- BP: 104/57 mmHg, HR: 59 bpm, RR: 20 breaths/minute, SnO₂: 95%
- Temp: 38.5°C
- Lab Values: Hb: 11.1 g/dL. WBC: 12.60x10⁹/L (from 9.5 on admission). Plt: 318x10⁹/L
- On examination: well, no complaints, no cough

From day 3 to day 4

- In view of nosocomial fever and WBC 12.60x10⁹/L. unclear source of infection, blood and urine cultures were sent
- CXR, PCT, CRP, 2nd round of COVID-19 testing ordered

Piperacillin-tazobactam 4.5g q6h started

- CXR, PCT, CRP, 2nd round of COVID-19 testing ordered
- After 3 hours + CRP: 53 mg/dL (up from 5 on admission). PCT < 0.06 ng/mL
- · Patient was afebrile
- CXR report: lungs showed neither congestion nor consolidation
- COVID-19 testing negative
- Blood and urine cultures pending
- · AMS team review: patient remained afebrile, hemodynamically stable and clinically well
- Only single spike of fever overnight, PCT normal, CXR - no consolidation
- Blood and urine cultures negative
- Decision to discontinue piperacillin-tazobactam

Patient outcome

On day 4

Patient was finally discharged on day 4 evening, after confirmation of negative COVID-19 via two rounds of testing and negative bacterial cultures (blood and urine).


CONCLUSIONS

- CRP, WBC and fever are not specific for bacterial infection/pneumonia.
- Use of PCT can rule out bacterial infection with precision, and there is no need to finish a course of antibiotics if bacterial infection is ruled out.
- PCT has value for individual patient management and as part of the hospital AMS program.

Supportive literature

. Liew YX, Lee W, Loh JC, et al. Impact of an antimicrobial stewardship programme on patient safety in Singapore General Hospital. Int J Antimicrob Agents. 2012;40:55-60

Loo LW, Liew YX, Lee W, Lee LW, Chlebicki P, Kwa AL, Discontinuation of antibiotic therapy within 24 hours of treatment initiation for patients with no clinical evidence of bacterial infection; a 5-year safety and outcome study from Singapore General Hospital Antimicrobial Stewardship Program. Int J Antimicrob Agents. 2019;53(5):606-611



CONCLUDING REMARKS

The cases presented in this booklet give an in-depth view on the best use of PCT, namely, serial testing and in combination with a thorough clinical and laboratory assessment also including diagnostic tests from microbiology.

The **most important rules for use of PCT in clinical practice may** be summarized as follows:

- in the context of a low-risk situation and a low pre-test probability for bacterial infections (e.g., bronchitis patient), a low PCT level <0.25 ng/mL or <0.1 ng/mL aids in ruling-out bacterial infection and empiric antibiotic therapy may be avoided.
- if PCT is increased or the initial clinical assessment shows a high suspicion for bacterial infection, antibiotics should be considered and PCT testing every 24-48 hours can be used to stop antibiotics if PCT drops to levels ≤0.25 ng/mL or decreases by 80% or more from its peak (Figure 1, page 43).
- in the context of a high-risk patient with sepsis, it is important that initial antibiotics should be used irrespective of PCT results, but a low PCT value may prompt additional diagnostic measures to rule out other non-bacterial causes of illness. In these situations, monitoring of PCT over time helps to track resolution of infection and decisions regarding early discontinuation of antibiotic treatment (Figure 2, page 44).

The algorithms in Figures 1 and 2 are taken from the latest **International Experts Consensus** paper (Schuetz et al. *Clin Chem Lab Med*, 2019) which refined established PCT algorithms by incorporating **severity of illness and probability of bacterial infection**. Furthermore, to simplify practical application, the fixed cut-offs were reduced to only one for **mild or moderate disease (0.25 ng/mL)** and one for **severe disease (0.5 ng/mL)**.

PCT has shown great promise for the personalization of antibiotic treatment, leading to an overall reduction in antibiotic exposure, fewer (or "less") side effects and improvements in clinical outcomes.

PCT measurements should always be interpreted in the context of the overall assessment of each patient, and should never delay the initiation of treatment in high-risk patients and critical states. However, PCT can then be used to monitor resolution of infection and therefore length of treatment.

The use of PCT requires **experience**, **education and training** as well as **case-based discussions** with experts and health professionals from different areas. For this purpose, this booklet is well suited and will hopefully help provide practitioners with important take-home messages to share with their colleagues.

Professor Philipp Schuetz, MD, MPH

Head of Internal Medicine and Emergency Medicine, Kantonsspital Aarau, Tellstrasse H7, CH-5001 Aarau, Professorship and faculty at the University of Basel, Switzerland



Figure 1. Use of PCT in patients with moderate illness outside the ICU Adapted by Prof. Schuetz from Schuetz P. et al. <i>Clin Chem Lab Med</i> . 2019;57(9):1308-18				
Initial clinical assessment (including microbiology)	BACTERIAL INFECTION UNCERTAIN		BACTERIAL INFECTION SUSPECTED	
PCT (ng/mL)	<0.25 ≥0.25		<0.25 ≥0.25	
Probability of bacterial infection based on PCT level	LOW Probability	HIGH PROBABILITY	LOW Probability	HIGH Probability
PCT interpretation	BACTERIAL INFECTION UNLIKELY	BACTERIAL INFECTION LIKELY	BACTERIAL INFECTION POSSIBLE	BACTERIAL INFECTION HIGHLY LIKELY
Antibiotic Management	Initiate empiric antibiotic regimen based on clinical judgement; consider other diagnostic tests	Initiate empiric antibiotic regimen based on clinical judgement	Initiate empiric antibiotic regimen based on clinical judgement; consider other diagnostic tests	Initiate appropriate empiric or targeted antibiotic regimen based on clinical judgement
PCT Monitoring	Repeat PCT within 6-24h and discontinue antibiotics if PCT still <0.25 ng/mL	Repeat PCT every 24-48h and discontinue antibiotics when PCT <0.25 ng/mL or decreases by 80%	Repeat PCT within 6-24h and discontinue antibiotics if PCT still <0.25 ng/mL	Repeat PCT every 24-48h and discontinue antibiotics when PCT <0.25 ng/mL or decreases by 80%

Figure 2. Use of PCT in patients with severe illness in the ICU Adapted by Prof. Schuetz from Schuetz P. et al. *Clin Chem Lab Med*. 2019;57(9):1308-18

Initial clinical assessment (including microbiology)	ent BACTERIAL INFECTION		BACTERIAL INFECTION SUSPECTED	
PCT (ng/mL)	<0.5	≥0.5	<0.5	≥0.5
Probability of bacterial infection based on PCT level	LOW Probability	HIGH PROBABILITY	LOW Probability	HIGH Probability
PCT Interpretation	BACTERIAL INFECTION UNLIKELY	BACTERIAL INFECTION LIKELY	BACTERIAL INFECTION POSSIBLE	BACTERIAL INFECTION HIGHLY LIKELY
Antibiotic Management	Initiate empiric antibiotic regimen based on clinical judgement; consider other diagnostic tests	Initiate empiric antibiotic regimen based on clinical judgement	Initiate empiric antibiotic regimen based on clinical judgement; consider other diagnostic tests	Initiate appropriate empiric or targeted antibiotic regimen based on clinical judgement
PCT Monitoring	Repeat PCT within 24-48h and discontinue antibiotics if PCT still <0.5 ng/mL	Repeat PCT every 24-48h and discontinue antibiotics when PCT <0.5 ng/mL or decreases by 80%	Repeat PCT within 24-48h and discontinue antibiotics if PCT still <0.5 ng/mL	Repeat PCT every 24-48h and discontinue antibiotics when PCT <0.5 ng/mL or decreases by 80%

ABBREVIATIONS AND ACRONYMS

AMS	antimicrobial stewardship
ARDS	acute respiratory distress syndrome
BiPAP	bilevel positive airway pressure
BMI	body mass index
BNP	brain natriuretic peptide
BPH	benign prostatic hyperplasia
BP	blood pressure
CAP	community-acquired pneumonia
CBG	capillary blood glucose
CHR	chronic heart failure
COPD	chronic obstructive pulmonary disorder
COVID-19	coronavirus disease 2019
CPAP	continuous positive airway pressure
CRP	C-reactive protein
СТ	computerized tomography
CVC	central venous catheter
CXR	chest X-ray
ECMO	extracorporeal membrane oxygenation
ED	emergency department
ER	emergency room
ESBL	extended spectrum beta-lactamase
FBC	full blood count

FiO ₂	fraction of inspired oxygen
GCS	Glasgow Coma Scale
Hb	hemoglobin
HLD	hyperlipidemia
HR	heart rate
HT/HTN	hypertension
ICU	intensive care unit
IHD	ischemic heart disease
IL-6	interleukin-6
LRTI	lower respiratory tract infection
MDRO	multi-drug resistant organism
mmHg	millimeters of mercury
Ν	nitrogen
NA	noradrenaline
NT-proBNP	N-terminal prohormone of brain natriuretic peptide
OHGA	oral hypoglycemic agent
OSAS	obstructive sleep apnea syndrome
PaCO ₂	partial pressure of carbon dioxide
PaO ₂	partial pressure of arterial oxygen
PCR	polymerase chain reaction
PCT	procalcitonin
PEEP	positive end expiratory pressure

CI



ABBREVIATIONS AND ACRONYMS

Plt	platelets
PO ₂	partial pressure of oxygen
qSOFA	quick Sequential Organ Failure Assessment
RA	room air
RSV	respiratory syncytial virus
rtPA	recombinant tissue plasminogen activator
RR	respiratory rate
SARS-CoV-2	severe acute respiratory syndrome coronavirus 2
ScvO ₂	central venous oxygen saturation
SOB	shortness of breath
SOFA	Sequential Organ Failure Assessment
SpO ₂	oxygen saturation
T2DM	type 2 diabetes mellitus
TAPSE	tricuspid annular plane systolic excursion
Temp/T	temperature
TLC	total lung capacity
URTI	upper respiratory tract infection
WBC	white blood cell count



bioMérieux In vitro diagnostics serving public health

A major player in *in vitro* diagnostics for more than 50 years, bioMérieux has always been driven by a pioneering spirit and unrelenting commitment to improve public health worldwide.

Our diagnostic solutions bring high medical value to healthcare professionals, providing them with the most relevant and reliable information, as quickly as possible, to support treatment decisions and better patient care.

bioMérieux's mission entails a commitment to support medical education, by promoting access to diagnostic knowledge for as many people as possible. Focusing on the medical value of diagnostics, our collection of educational booklets aims to raise awareness of the essential role that diagnostic test results play in healthcare decisions.

Other educational booklets are available. Consult your local bioMérieux representative, or visit www.biomerieux.com/en/education/educational-booklets

The information in this booklet is for educational purposes only and is not intended to be exhaustive. It is not intended to be a substitute for professional medical advice. Always consult a medical director, physician, or other qualified health provider regarding processes and/or protocols for diagnosis and treatment of a medical condition. bioMérieux assumes no responsibility or liability for any diagnosis established or treatment prescribed by the physician.

bioMérieux S.A. • 69280 Marcy l'Étoile • France Tel.: + 33 (0)4 78 87 20 00 • Fax: +33 (0)4 78 87 20 90 www.biomerieux.com